Myriad Genetics Inc (MYGN)
Cash conversion cycle
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Days of inventory on hand (DOH) | days | 39.80 | 37.63 | 38.38 | 37.16 | 34.00 | 40.09 | 37.11 | 37.32 | 36.32 | 36.90 | 29.38 | 29.16 | 28.26 | 34.13 | 33.08 | 50.36 | 55.54 | 53.76 | 57.07 | 56.21 |
Days of sales outstanding (DSO) | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Cash conversion cycle | days | 39.80 | 37.63 | 38.38 | 37.16 | 34.00 | 40.09 | 37.11 | 37.32 | 36.32 | 36.90 | 29.38 | 29.16 | 28.26 | 34.13 | 33.08 | 50.36 | 55.54 | 53.76 | 57.07 | 56.21 |
December 31, 2024 calculation
Cash conversion cycle = DOH + DSO – Number of days of payables
= 39.80 + — – —
= 39.80
The cash conversion cycle of Myriad Genetics Inc has shown fluctuations over the periods analyzed. In general, a decreasing trend is observed from March 31, 2020, to June 30, 2021, indicating an improvement in managing the company's working capital. During this period, the company was able to convert its inventory into cash at a faster rate.
From June 30, 2021, to September 30, 2022, there was a slight increase in the cash conversion cycle, suggesting a potential delay in collecting cash from customers or managing inventory efficiently. This increase could be a red flag for the company's liquidity and operational efficiency.
Subsequently, from September 30, 2022, to December 31, 2024, the cash conversion cycle remained relatively stable with slight fluctuations. Although the cycle increased slightly towards the end of the period, it stayed within a manageable range.
Overall, the cash conversion cycle of Myriad Genetics Inc reflects the company's ability to efficiently manage its working capital, but there are periods of concern that may require closer monitoring and management attention to ensure optimal liquidity and operational performance.
Peer comparison
Dec 31, 2024